---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-247694"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2021-08-16T23:59:59+00:00"
generated_at: "2026-06-29T10:01:36.939105+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences Q2 net loss $18.7M; cash $249M; next IGNITE DMD dose in Q4 2021

## Summary
- Collaboration revenue of $3.6M vs $0 in prior year from Ultragenyx deal.
- R&D expenses $15.5M (up from $13.4M) driven by SGT-001 manufacturing and clinical costs.
- Cash, cash equivalents and securities $249M as of June 30, 2021; runway into Q4 2022.
- IGNITE DMD trial: next patient dosing anticipated Q4 2021; no new safety findings in patients 1-8 over 90 days to >3 years.
- Targeting IND submission for next-generation SGT-003 in early-2023.

## SEC filing metadata
- accession: 0001193125-21-247694
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2021-08-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312521247694/0001193125-21-247694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312521247694/d200956d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-247694
- JSON: https://secwatch.observer/filing/0001193125-21-247694.json
- Plain text: https://secwatch.observer/filing/0001193125-21-247694.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.